abstract: BACKGROUND: Topical antifungals comprising @entity8304 derivatives have been used for the treatment of @entity6509 previously, owing to their anti-inflammatory activities. @entity8974 , an antifungal agent belongs to @entity4974 group, has also anti-inflammatory effects. Currently, there are only a few unpublished studies, in which @entity8974 has been used systemically for @entity6509 treatment. AIMS: In this single-blind, 8-week study, we investigated the potential efficacy and safety of @entity8974 1% cream for the treatment of mild and moderate @entity6509 , and compared the results with those of 0.75% @entity868 gel. @entity1 /METHODS: Forty @entity1 , 30 females and 10 males, with @entity6509 were enrolled into the study between 2006 and 2007 years. Twenty of the @entity1 were instructed to apply 1% @entity8974 cream, whereas others @entity1 of the study population were instructed to use 0.75% @entity868 gel. A total of 32 @entity1 completed the study. Pre-treatment and post-treatment total severity score (TSS) of the disease were determined by assessing the severity of @entity8721 , and the number of papules/pustules of the whole face. The overall response rates, differences of pre-/post-treatment scores of each criterium and the percentages of the decrease in TSS of the study groups were compared statistically. RESULTS: There was no statistically significant difference between the groups in terms of age, sex, and disease duration (P = 0.937, 1.000, and 0.055, respectively). No significant difference was found between the mean post-treatment TSSs of the two groups (P = 0.605). The percentage of clearance assessed by the differences between pre-treatment and post-treatment TSSs was 55% in @entity8974 group, although the percentage was 45% in @entity868 group, with no statistically significant difference between the groups (P = 0.496). Local side effects including erythema, @entity111 , and burning were mild and transient in both groups, with similar frequencies (P = 0.101). CONCLUSION: This preliminary study suggests that 1% @entity8974 cream is an effective and safe treatment for @entity6509 , and can be an option for @entity1 who cannot tolerate other modalities.

title: Efficacy of 1% XXXX cream in comparison with 0.75% @entity868 gel for the treatment of @entity6509 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity8974 :: ('MESH:C041359', 'Chemical') :: ['Terbinafine', 'terbinafine']

entities_list: @entity868 :: ('MESH:D008795', 'Chemical') :: ['metronidazole']

entities_list: @entity8721 :: ('MESH:D013684', 'Disease') :: ['erythema/telangiectasia']

entities_list: @entity8304 :: ('MESH:C029899', 'Chemical') :: ['imidazole']

entities_list: @entity111 :: ('MESH:D011537', 'Disease') :: ['pruritus']

entities_list: @entity4974 :: ('MESH:D000499', 'Chemical') :: ['allylamine']

entities_list: @entity6509 :: ('MESH:D012393', 'Disease') :: ['papulopustular rosacea', 'rosacea']

answer: @entity8974 :: (MESH:C041359,Chemical) :: ['terbinafine']


abstract: BACKGROUND: Topical antifungals comprising @entity8304 derivatives have been used for the treatment of @entity6509 previously, owing to their anti-inflammatory activities. @entity8974 , an antifungal agent belongs to @entity4974 group, has also anti-inflammatory effects. Currently, there are only a few unpublished studies, in which @entity8974 has been used systemically for @entity6509 treatment. AIMS: In this single-blind, 8-week study, we investigated the potential efficacy and safety of @entity8974 1% cream for the treatment of mild and moderate @entity6509 , and compared the results with those of 0.75% @entity868 gel. @entity1 /METHODS: Forty @entity1 , 30 females and 10 males, with @entity6509 were enrolled into the study between 2006 and 2007 years. Twenty of the @entity1 were instructed to apply 1% @entity8974 cream, whereas others @entity1 of the study population were instructed to use 0.75% @entity868 gel. A total of 32 @entity1 completed the study. Pre-treatment and post-treatment total severity score (TSS) of the disease were determined by assessing the severity of @entity8721 , and the number of papules/pustules of the whole face. The overall response rates, differences of pre-/post-treatment scores of each criterium and the percentages of the decrease in TSS of the study groups were compared statistically. RESULTS: There was no statistically significant difference between the groups in terms of age, sex, and disease duration (P = 0.937, 1.000, and 0.055, respectively). No significant difference was found between the mean post-treatment TSSs of the two groups (P = 0.605). The percentage of clearance assessed by the differences between pre-treatment and post-treatment TSSs was 55% in @entity8974 group, although the percentage was 45% in @entity868 group, with no statistically significant difference between the groups (P = 0.496). Local side effects including erythema, @entity111 , and burning were mild and transient in both groups, with similar frequencies (P = 0.101). CONCLUSION: This preliminary study suggests that 1% @entity8974 cream is an effective and safe treatment for @entity6509 , and can be an option for @entity1 who cannot tolerate other modalities.

title: Efficacy of 1% @entity8974 cream in comparison with 0.75% @entity868 gel for the treatment of XXXX .

answer: @entity6509 :: (MESH:D012393,Disease) :: ['papulopustular rosacea']


abstract: BACKGROUND: Topical antifungals comprising @entity8304 derivatives have been used for the treatment of @entity6509 previously, owing to their anti-inflammatory activities. @entity8974 , an antifungal agent belongs to @entity4974 group, has also anti-inflammatory effects. Currently, there are only a few unpublished studies, in which @entity8974 has been used systemically for @entity6509 treatment. AIMS: In this single-blind, 8-week study, we investigated the potential efficacy and safety of @entity8974 1% cream for the treatment of mild and moderate @entity6509 , and compared the results with those of 0.75% @entity868 gel. @entity1 /METHODS: Forty @entity1 , 30 females and 10 males, with @entity6509 were enrolled into the study between 2006 and 2007 years. Twenty of the @entity1 were instructed to apply 1% @entity8974 cream, whereas others @entity1 of the study population were instructed to use 0.75% @entity868 gel. A total of 32 @entity1 completed the study. Pre-treatment and post-treatment total severity score (TSS) of the disease were determined by assessing the severity of @entity8721 , and the number of papules/pustules of the whole face. The overall response rates, differences of pre-/post-treatment scores of each criterium and the percentages of the decrease in TSS of the study groups were compared statistically. RESULTS: There was no statistically significant difference between the groups in terms of age, sex, and disease duration (P = 0.937, 1.000, and 0.055, respectively). No significant difference was found between the mean post-treatment TSSs of the two groups (P = 0.605). The percentage of clearance assessed by the differences between pre-treatment and post-treatment TSSs was 55% in @entity8974 group, although the percentage was 45% in @entity868 group, with no statistically significant difference between the groups (P = 0.496). Local side effects including erythema, @entity111 , and burning were mild and transient in both groups, with similar frequencies (P = 0.101). CONCLUSION: This preliminary study suggests that 1% @entity8974 cream is an effective and safe treatment for @entity6509 , and can be an option for @entity1 who cannot tolerate other modalities.

title: Efficacy of 1% @entity8974 cream in comparison with 0.75% XXXX gel for the treatment of @entity6509 .

answer: @entity868 :: (MESH:D008795,Chemical) :: ['metronidazole']


abstract: The objective of this study was to determine if localized ischaemia of the caput epididymis in the ram causes morphological changes similar to those characteristic of @entity3892 in @entity1 . This was tested by performing unilateral occlusion of the superior epididymal artery in 10 rams. At the end of 4 (n = 5) or 28 weeks (n = 4), rams were castrated and the testes and epididymides were weighed. Analysis of histological sections at the light microscope level provided quantitative data on lumen diameter and epithelial cell height of the efferent ducts. Qualitative analysis and specific histochemical stains for identification of lipofuscin pigment provided further information on tissue changes. Electron microscopy was performed on the efferent ducts to assess ultrastructural changes. The results revealed that localized ischaemia of the proximal epididymis caused a dramatic change in tubule calibre of the efferent ducts and initial segment resulting in @entity3885 . These changes were more severe following 28 weeks of @entity432 . The epithelial cells of the proximal region showed an increase in the number of lysosomes and they became active in phagocytosis of spermatozoa. @entity6973 pigment accumulated within the epithelial cells and also in macrophage-like cells that had invaded the lumina, interstitium and intra-epithelial regions of the ducts. On the basis of these observations we conclude that the tissue changes which occur in the ram epididymis as a result of localized ischaemia show a striking similarity to those seen in @entity1 exhibiting @entity3892 . This suggests the possible implication of @entity455 in the aetiology of obstructive @entity3893 in @entity1 .

title: Effects of ischaemia on the caput epididymis and its relationship to XXXX : a qualitative study in the ram.

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular disorders']

entities_list: @entity3892 :: ('MESH:D004823', 'Disease') :: ['higher epididymal obstruction']

entities_list: @entity3885 :: ('MESH:D008173', 'Disease') :: ['obstruction of the distal lumina']

entities_list: @entity6973 :: ('MESH:D008062', 'Chemical') :: ['Lipofuscin']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['arterial occlusion']

entities_list: @entity3893 :: ('MESH:D053713', 'Disease') :: ['azoospermia']

answer: @entity3892 :: (MESH:D004823,Disease) :: ['higher epididymal obstruction']


abstract: The leading @entity311 vaccine candidate, RTS,S, targets the sporozoite and liver stages of the @entity3964 life cycle, yet it provides partial protection against disease associated with the subsequent blood stage of @entity281 . Antibodies against the vaccine target, the circumsporozoite protein, have not shown sufficient correlation with risk of clinical @entity311 to serve as a surrogate for protection. The mechanism by which a vaccine that targets the asymptomatic sporozoite and liver stages protects against disease caused by blood-stage parasites remains unclear. We hypothesized that vaccination with RTS,S protects from blood-stage disease by reducing the number of parasites emerging from the liver, leading to prolonged exposure to subclinical levels of blood-stage parasites that go undetected and untreated, which in turn boosts pre-existing antibody-mediated blood-stage immunity. To test this hypothesis, we compared antibody responses to 824 P. falciparum antigens by protein array in Mozambican @entity1 6 months after receiving a full course of RTS,S (n = 291) versus comparator vaccine (n = 297) in a Phase IIb trial. Moreover, we used a nested case-control design to compare antibody responses of @entity1 who did or did not experience febrile @entity311 . Unexpectedly, we found that the breadth and magnitude of the antibody response to both liver and asexual blood-stage antigens was significantly lower in RTS,S vaccinees, with the exception of only four antigens, including the RTS,S circumsporozoite antigen. Contrary to our initial hypothesis, these findings suggest that RTS,S confers protection against clinical @entity311 by blocking sporozoite invasion of hepatocytes, thereby reducing exposure to the blood-stage parasites that cause disease. We also found that antibody profiles 6 months after vaccination did not distinguish protected and susceptible @entity1 during the subsequent 12-month follow-up period but were strongly associated with exposure. Together, these data provide insight into the mechanism by which RTS,S protects from @entity311 .

title: RTS,S Vaccination Is Associated With Serologic Evidence of Decreased Exposure to XXXX Liver- and Blood-Stage Parasites.

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity3964 :: ('5833', 'Species') :: ['Plasmodium falciparum']

answer: @entity3964 :: (5833,Species) :: ['Plasmodium falciparum']


abstract: We monitored ST segment continuously for at least 3 h after the beginning of lytic treatment in 103 @entity1 undergoing early coronary thrombolysis for acute @entity583 in order to ascertain whether this technique, which has been shown to be useful to assess recanalization of the @entity1188 , is also able to identify the improvement in left ventricular function associated with successful reperfusion. Global left ventricular function (assessed in the 30 degrees right anterior oblique projection with the area/length method) and @entity1188 zone wall motion (studied with the centerline method) were evaluated at least 4 weeks after the event. Reperfusion was thought to be achieved when ST segment elevation dropped > 50% relative to the most abnormal peak documented at any time in the study. Eighty @entity1 (78%) met the criterium for successful reperfusion (group 1), and 23 (22%) did not (group 2). Both groups had similar clinical and angiographic characteristics. All indexes of global left ventricular function were significantly better in group 1 than in group 2 @entity1 (end-diastolic volume: 176 +/- 51 vs. 209 +/- 76 ml, end-systolic volume: 66 +/- 40 vs. 97 +/- 55 ml, ejection fraction: 65 +/- 13 vs. 57 +/- 11%, respectively, all P < 0.02). Also the severity (-1.6 +/- 1.3 vs. -2.6 +/- 1.01 S.D./chord, respectively, P < 0.001) and the extension of @entity2845 in the @entity1188 zone (number of chords with > 2 S.D.: 13 +/- 16 vs. 28 +/- 17, respectively, P < 0.0001) were less in group 1 than in group 2 @entity1 . Furthermore, in reperfused @entity1 , both global left ventricular function and regional wall motion were better in those admitted < 60 min from onset of @entity158 . In conclusion, @entity1 with rapid ( > 50%) decrease of ST segment elevation have smaller @entity1188 size and better global left ventricular function than @entity1 without electrocardiographic signs of reperfusion as assessed by continuous ST segment monitoring. This suggests that this non-invasive technique is a powerful tool able to identify @entity1 most benefiting from thrombolytic therapy.

title: Non-invasive assessment of reperfusion of the XXXX during coronary thrombolysis and its relation with left ventricular function.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2845 :: ('MESH:D018476', 'Disease') :: ['hypokinesia']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct-related artery', 'infarct']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

answer: @entity1188 :: (MESH:D007238,Disease) :: ['infarct-related artery']


abstract: AIM: To study the dynamic and long-lasting expression of @entity7102 receptor after acute @entity1779 ( @entity1779 ) in @entity35 . METHODS: 36 @entity35 were randomly divided into 6 groups (n = 6): Normal group and @entity1779 model groups at 6 hours, 24 hours, 3 days, 7 days and 14 days. @entity1779 models were produced with the induction of collagenase type VII-S. Immunohistochemical method was used to detect @entity8225 protein and RT-PCR technique was used to detect @entity8225 mRNA in brain tissue around the haematoma in different groups. RESULTS: @entity8225 protein and mRNA were mild positive in normal group. In model groups, intensity of @entity8225 expression started to enhance at 6 hours, and enhanced more at 24 hours. @entity8225 expression reached the peak at 3 days and began to descend. At 7 days the descent was obvious and there was further descent at 14 days. At each time point, the @entity8225 protein positive cell number and @entity8225 mRNA absorbance ratio in @entity1779 model groups were significantly higher than those in normal group (P < 0.05 or P < 0.01). In addition, @entity8225 proteins were obviously expressed in vivo in brain capillary endothelial cell. CONCLUSION: Functional @entity8225 exists in brain capillary endothelial cells. Activation of @entity8225 after @entity1779 due to the stimulation of @entity7102 is not only the initiating agent of @entity2657 after @entity1779 , but also participates the development of @entity2657 .

title: [Dynamic and long-lasting expression of XXXX receptor-1 after @entity1779 in @entity35 ].

entities_list: @entity2657 :: ('MESH:D001929', 'Disease') :: ['cerebral edema']

entities_list: @entity1779 :: ('MESH:D002543', 'Disease') :: ['ICH', 'intracerebral hemorrhage']

answer: @entity7102 :: (29251(Tax:10116),Gene) :: ['thrombin']


abstract: AIM: To study the dynamic and long-lasting expression of @entity7102 receptor after acute @entity1779 ( @entity1779 ) in @entity35 . METHODS: 36 @entity35 were randomly divided into 6 groups (n = 6): Normal group and @entity1779 model groups at 6 hours, 24 hours, 3 days, 7 days and 14 days. @entity1779 models were produced with the induction of collagenase type VII-S. Immunohistochemical method was used to detect @entity8225 protein and RT-PCR technique was used to detect @entity8225 mRNA in brain tissue around the haematoma in different groups. RESULTS: @entity8225 protein and mRNA were mild positive in normal group. In model groups, intensity of @entity8225 expression started to enhance at 6 hours, and enhanced more at 24 hours. @entity8225 expression reached the peak at 3 days and began to descend. At 7 days the descent was obvious and there was further descent at 14 days. At each time point, the @entity8225 protein positive cell number and @entity8225 mRNA absorbance ratio in @entity1779 model groups were significantly higher than those in normal group (P < 0.05 or P < 0.01). In addition, @entity8225 proteins were obviously expressed in vivo in brain capillary endothelial cell. CONCLUSION: Functional @entity8225 exists in brain capillary endothelial cells. Activation of @entity8225 after @entity1779 due to the stimulation of @entity7102 is not only the initiating agent of @entity2657 after @entity1779 , but also participates the development of @entity2657 .

title: [Dynamic and long-lasting expression of @entity7102 receptor-1 after XXXX in @entity35 ].

answer: @entity1779 :: (MESH:D002543,Disease) :: ['intracerebral hemorrhage']


abstract: AIM: To study the dynamic and long-lasting expression of @entity7102 receptor after acute @entity1779 ( @entity1779 ) in @entity35 . METHODS: 36 @entity35 were randomly divided into 6 groups (n = 6): Normal group and @entity1779 model groups at 6 hours, 24 hours, 3 days, 7 days and 14 days. @entity1779 models were produced with the induction of collagenase type VII-S. Immunohistochemical method was used to detect @entity8225 protein and RT-PCR technique was used to detect @entity8225 mRNA in brain tissue around the haematoma in different groups. RESULTS: @entity8225 protein and mRNA were mild positive in normal group. In model groups, intensity of @entity8225 expression started to enhance at 6 hours, and enhanced more at 24 hours. @entity8225 expression reached the peak at 3 days and began to descend. At 7 days the descent was obvious and there was further descent at 14 days. At each time point, the @entity8225 protein positive cell number and @entity8225 mRNA absorbance ratio in @entity1779 model groups were significantly higher than those in normal group (P < 0.05 or P < 0.01). In addition, @entity8225 proteins were obviously expressed in vivo in brain capillary endothelial cell. CONCLUSION: Functional @entity8225 exists in brain capillary endothelial cells. Activation of @entity8225 after @entity1779 due to the stimulation of @entity7102 is not only the initiating agent of @entity2657 after @entity1779 , but also participates the development of @entity2657 .

title: [Dynamic and long-lasting expression of @entity7102 receptor-1 after @entity1779 in XXXX ].

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: Long-term follow-up studies after endovascular treatment for @entity438 are still rare and inconclusive. The aim of this study was to assess long-term clinical and angiographic outcome of @entity1 with endovascularly treated @entity439 . The Clinical outcome of all 185 @entity1 with endovascularly treated @entity439 were analyzed and 77 out of 122 surviving @entity1 were examined with MRI and MRA nine to 16 years (mean 11 years) after the initial endovascular treatment. Sixty-three @entity1 were deceased at the time of follow-up. The cause of @entity204 was @entity439 -related in 34 (54%) @entity1 . The annual rebleeding rate from the treated @entity439 was 1.3% in the ruptured group and 0.1% in the unruptured group. In long-term follow-up MRA 18 @entity439 (53%) were graded as complete, 11 @entity439 (32%) had neck remnants and five @entity439 (15%) were @entity2300 in the ruptured group. Occlusion grade was lower in the unruptured group with 20 @entity439 (41%) graded as complete, 11 (22%) had neck remnants and 18 (37%) were incomplete. However, only three @entity439 were unstable during the follow-up period and needed retreatment. Endovascular treatment of unruptured @entity439 showed incomplete angiographic outcome in 37% of cases. However, @entity548 rate was as low as 0.1%. Endovascular treatment of @entity1756 showed incomplete angiographic outcome in 15% of cases and the annual rebleeding rate was 1.3%.

title: Long-term follow-up study of endovascularly treated XXXX .

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['annual bleeding']

entities_list: @entity1756 :: ('MESH:D017542', 'Disease') :: ['ruptured aneurysms']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms', 'aneurysm']

entities_list: @entity2300 :: ('MESH:D011681', 'Disease') :: ['incompletely occluded']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['intracranial aneurysm']

answer: @entity438 :: (MESH:D002532,Disease) :: ['intracranial aneurysms']


abstract: OBJECTIVE: @entity3237 modulates food reward via central @entity3237 receptor ( @entity18070 ) expressing neurons. Food reward requires stimulation of midbrain @entity935 neurons and is modulated by central @entity3237 action, but the exact central mechanisms remain unclear. Stimulatory and inhibitory @entity3237 actions on @entity935 neurons have been reported, e.g. by indirect actions on orexin neurons or via direct innervation of @entity935 neurons in the ventral tegmental area. METHODS: We showed earlier that @entity18070 neurons in the @entity2339 ( @entity2339 ) co-express the inhibitory acting neuropeptide @entity17234 (GAL- @entity18070 neurons). We studied the involvement of GAL- @entity18070 neurons to regulate nutrient reward in @entity19 with selective @entity18070 deletion from @entity17234 neurons (GAL- @entity18070 (KO) @entity19 ). RESULTS: We found that the rewarding value and preference for @entity969 over fat was increased in GAL- @entity18070 (KO) @entity19 compared to controls. @entity2339 GAL- @entity18070 neurons innervate orexin neurons, but not the VTA. Further, expression of @entity17234 and its receptor @entity40335 are decreased in the @entity2339 of GAL- @entity18070 (KO) @entity19 , resulting in increased activation of orexin neurons. CONCLUSION: We suggest @entity17234 as an important mediator of @entity3237 action to modulate nutrient reward by inhibiting orexin neurons.

title: @entity3237 modulates nutrient reward via inhibitory XXXX action on orexin neurons.

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine']

entities_list: @entity969 :: ('MESH:D013395', 'Chemical') :: ['sucrose']

entities_list: @entity2339 :: ('MESH:D007029', 'Disease') :: ['LHA', 'lateral hypothalamus']

answer: @entity17234 :: (14419(Tax:10090),Gene) :: ['galanin']


abstract: OBJECTIVE: @entity3237 modulates food reward via central @entity3237 receptor ( @entity18070 ) expressing neurons. Food reward requires stimulation of midbrain @entity935 neurons and is modulated by central @entity3237 action, but the exact central mechanisms remain unclear. Stimulatory and inhibitory @entity3237 actions on @entity935 neurons have been reported, e.g. by indirect actions on orexin neurons or via direct innervation of @entity935 neurons in the ventral tegmental area. METHODS: We showed earlier that @entity18070 neurons in the @entity2339 ( @entity2339 ) co-express the inhibitory acting neuropeptide @entity17234 (GAL- @entity18070 neurons). We studied the involvement of GAL- @entity18070 neurons to regulate nutrient reward in @entity19 with selective @entity18070 deletion from @entity17234 neurons (GAL- @entity18070 (KO) @entity19 ). RESULTS: We found that the rewarding value and preference for @entity969 over fat was increased in GAL- @entity18070 (KO) @entity19 compared to controls. @entity2339 GAL- @entity18070 neurons innervate orexin neurons, but not the VTA. Further, expression of @entity17234 and its receptor @entity40335 are decreased in the @entity2339 of GAL- @entity18070 (KO) @entity19 , resulting in increased activation of orexin neurons. CONCLUSION: We suggest @entity17234 as an important mediator of @entity3237 action to modulate nutrient reward by inhibiting orexin neurons.

title: XXXX modulates nutrient reward via inhibitory @entity17234 action on orexin neurons.

answer: @entity3237 :: (16846(Tax:10090),Gene) :: ['Leptin']


abstract: OBJECTIVE: To explore the dynamic magnetic resonance (MR) imaging findings of @entity1358 and evaluate its pathological correlation. METHODS: Twelve cases with @entity1358 confirmed by surgical pathology underwent MR plain scanning and dynamic enhancement scanning before operation. And the MR data were reviewed and analyzed retrospectively in comparison with surgical and pathological results. RESULTS: Twelve lesions were located in right kidney (n = 9) and left kidney (n = 3) with a mean @entity5 diameter of 7.3 cm (range: 3.2 - 12.6 cm). They were located in renal cortex (n = 1), renal medulla (n = 9) and the middle of cortex and medulla with a relatively normal renal shape. Nine lesions appeared global and 3 elliptic in shape. Well-defined margin was showed in 12 lesions and a thin capsule was observed in all lesions. The @entity5 presented a low to middle homogeneous signal intensity on T1WI and intermediates homogeneous signal intensity on fat saturated FSE-T2WI with a hypointense thin capsule and a hyperintense central scar. A mild-to-middle degree of @entity5 enhancement in cortical phase ( @entity5 SI change 120.3% with a standard deviation of 84.3 and a median of 115.2%) was slightly lower, isointense or slightly higher than renal medulla. And obvious enhancement in portal venous phase( @entity5 SI change 173.7% with a standard deviation of 92.4 and a median of 171.5%) was lower than renal medulla. CONCLUSION: @entity1358 typically forms large and well-circumscribed global solid masses in renal medulla. With a relatively normal renal shape and a thin capsule, it shows intermediate homogeneous signal intensity on T1WI and T2WI. And a middle degree enhancement with central stellate scar is found in some @entity1 .

title: [Pathological correlation of dynamic magnetic resonance findings for XXXX ].

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['chromophobe cell renal carcinoma', 'Chromophobe cell renal carcinoma']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['chromophobe cell renal carcinoma']


abstract: BACKGROUND: Adhesion molecules play an important role in the development and progression of @entity453 . The aim of this study was to compare concentrations of soluble forms of adhesion molecules in @entity1 with different clinical presentations of @entity453 ( @entity453 ). METHODS: One hundred and twenty-eight @entity1 with @entity453 were divided into three groups; the first group was @entity583 group (AMI group, n = 45), the second group was unstable @entity951 group (UAP group, n = 48), the third group was stable @entity951 group ( @entity13551 group, n = 35). We compared them with @entity1 with normal coronary arteries (control group, n = 31). The serum levels of vascular cell adhesion molecule ( @entity4725 ), @entity2071 ( @entity2071 ), @entity4105 and @entity8729 were measured in all subjects. RESULTS: The serum level of @entity4725 in the AMI group was significantly higher than in the UAP, @entity13551 and control groups (P < 0.01). The level in the UAP group was significantly higher than the @entity13551 group and control group (P < 0.01) and the level in the @entity13551 group was significantly higher than in the control group (P < 0.01). The serum @entity2071 level was significantly elevated in the AMI, UAP and @entity13551 groups as compared to the control group (P < 0.01). The levels of serum @entity4105 and @entity8729 in the AMI and UAP groups were significantly higher than in the @entity13551 and control groups (P < 0.01). CONCLUSIONS: Increased levels of @entity4725 and @entity2071 , @entity4105 and @entity8729 , as markers of @entity32 , showed the importance of inflammatory processes in the development of @entity731 and clinical expression of @entity453 . Soluble @entity2071 , @entity4725 , @entity4105 and @entity8729 concentrations are useful indicators of the presence of @entity731 and the severity of @entity453 clinical presentation.

title: Levels of soluble adhesion molecules in @entity1 with various clinical presentations of XXXX .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['acute myocardial infarction']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity951 :: ('MESH:D000787', 'Disease') :: ['angina pectoris']

entities_list: @entity2071 :: ('3383', 'Gene') :: ['ICAM-1', 'intercellular adhesion molecule-1']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['CAD', 'coronary artery disease', 'coronary atherosclerosis']

answer: @entity453 :: (MESH:D003324,Disease) :: ['coronary atherosclerosis']


abstract: BACKGROUND: Adhesion molecules play an important role in the development and progression of @entity453 . The aim of this study was to compare concentrations of soluble forms of adhesion molecules in @entity1 with different clinical presentations of @entity453 ( @entity453 ). METHODS: One hundred and twenty-eight @entity1 with @entity453 were divided into three groups; the first group was @entity583 group (AMI group, n = 45), the second group was unstable @entity951 group (UAP group, n = 48), the third group was stable @entity951 group ( @entity13551 group, n = 35). We compared them with @entity1 with normal coronary arteries (control group, n = 31). The serum levels of vascular cell adhesion molecule ( @entity4725 ), @entity2071 ( @entity2071 ), @entity4105 and @entity8729 were measured in all subjects. RESULTS: The serum level of @entity4725 in the AMI group was significantly higher than in the UAP, @entity13551 and control groups (P < 0.01). The level in the UAP group was significantly higher than the @entity13551 group and control group (P < 0.01) and the level in the @entity13551 group was significantly higher than in the control group (P < 0.01). The serum @entity2071 level was significantly elevated in the AMI, UAP and @entity13551 groups as compared to the control group (P < 0.01). The levels of serum @entity4105 and @entity8729 in the AMI and UAP groups were significantly higher than in the @entity13551 and control groups (P < 0.01). CONCLUSIONS: Increased levels of @entity4725 and @entity2071 , @entity4105 and @entity8729 , as markers of @entity32 , showed the importance of inflammatory processes in the development of @entity731 and clinical expression of @entity453 . Soluble @entity2071 , @entity4725 , @entity4105 and @entity8729 concentrations are useful indicators of the presence of @entity731 and the severity of @entity453 clinical presentation.

title: Levels of soluble adhesion molecules in XXXX with various clinical presentations of @entity453 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: PURPOSE: @entity1 with @entity11 have a limited survival prognosis. We retrospectively analyzed data of @entity11 @entity1 with the aim of defining prognostic factors on which individualized treatment strategies might be built on. @entity1 AND METHODS: Seventy-six @entity1 with primary @entity11 (51 @entity463 multiforme, 20 @entity816 , 4 anaplastic oligo- @entity816 , 1 @entity11 ) were postoperatively irradiated with 5 and 8 Me V photons, 2 Gy per fraction to a median total dose of 60 Gy (range 50 to 70 Gy). RESULTS: The youngest quartile of @entity1 (up to 45 years) had the highest 3-year survival rates (mean +/- SE: 15 +/- 8%) and median survival time (17.9 months, 95% confidence interval: 9.2, 24.2 months) as compared to the oldest quartile (> 61 years) with no 3-year survivor and a median survival time of 9.7 months (7.2, 12.3 months). The middle quartiles (46 to 61 years) showed intermediate results. The difference between the youngest and oldest quartile (p = 0.01) and the middle quartile versus the oldest quartile (p = 0.04) was significant. In univariate analysis, @entity5 size (p = 0.04 for -30 mm vs > 50 mm) was of importance. In multivariate analysis only age of the @entity1 reached statistical significance (p = 0.03). As compared to the youngest quartile of @entity1 , the oldest quartile had a relative risk of 2.1 (95% confidence interval: 0.9, 5.1) of dying from the disease; the age group of 46 to 61 years had a relative risk of 2.0 (0.9, 4.3). CONCLUSIONS: Age of the @entity1 is the most important factor for survival prognosis favouring younger age (< or = 45 years). The possible implications for radiation therapy are discussed.

title: Prognostic factors in high-grade XXXX . A multivariate analysis of 76 cases with postoperative radiotherapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS']

entities_list: @entity11 :: ('MESH:D005910', 'Disease') :: ['anaplastic glioma', 'malignant glioma', 'malignant gliomas']

entities_list: @entity816 :: ('MESH:D001254', 'Disease') :: ['anaplastic astrocytoma', 'astrocytoma']

entities_list: @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma']

answer: @entity11 :: (MESH:D005910,Disease) :: ['malignant glioma']


abstract: BACKGROUND: Evidence supporting treatment intensification in @entity309 ( @entity309 ) is limited and controversial. We explored outcomes of infliximab dose increases and accounted for pre-existing trough levels in @entity1 with active @entity309 . METHODS: This study was a retrospective study of 42 @entity309 @entity1 who received increased infliximab following an insufficient response (DAS28 >3.2). Serum concentrations of infliximab and antibodies to infliximab (ATI) and DAS28 and EULAR clinical response parameters were recorded for 1   year. Analyses were performed in three @entity1 groups that were defined by infliximab serum concentration prior to treatment enhancement: no detectable, low (<1.1    g/mL) or high (>= 1.1    g/mL) drug levels. RESULTS: No circulating infliximab was detected in 20 @entity1 (47.6%), but 13 (31%) and 9 (21.4%) @entity1 exhibited low and high levels, respectively. ATI was only detected in @entity1 with no detectable drug levels because the drug interferes with ELISA. DAS28 disease activity globally showed a modest improvement after dose escalation, but this improvement did not persist after 6 and 12   months. Infliximab serum levels increased significantly in the high group (p   =   0.016), but no increase was achieved in the low and no detectable groups. The three study groups exhibited similar disease activity over time, and no improvement was observed in the non-responder EULAR rates. CONCLUSION: These results suggest that the efficacy of an infliximab dose increase is limited, and the response is independent of the infliximab trough serum concentration that is achieved prior to escalation.

title: Effect of Infliximab Dose Increase in XXXX at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

answer: @entity309 :: (MESH:D001172,Disease) :: ['Rheumatoid Arthritis']


abstract: OBJECTIVE: To investigate the reliability and feasibility of @entity1600 biopsy (SLNB) of @entity3557 using combination of lymphoscintigraphy, the gamma probe and @entity6693 staining techniques. METHODS: Twenty-three consecutive @entity1 with @entity3557 were entered in the study between August 2007 and August 2009. All cases were without clinical evidence of cervical lymph node involvement. The (99)Tc(m)-dextran of 74 MBq (2mCi) was injected intratumorally under ultrasound guidance about 2 h to 5 h prior to surgery. @entity6693 was injected around the @entity5 during surgery. Preoperative lymphoscintigraphy, intra-operative hand-held gamma probe detecting and @entity6693 staining techniques were used to detect the @entity1600 ( @entity1600 ). @entity1600 biopsies were sent to prepare frozen sections and the results were compared with specimen of routine selective neck dissection. RESULTS: The SLNs were identified in all cases with the combination techniques. The @entity1600 identification rates were 87.0% and 100% with @entity6693 staining and lymphoscintigraphy plus probe scanning, respectively. @entity3 in SLNs were revealed by frozen-section histology in 12 @entity1 . In one case, SLNs frozen-section were negative, but @entity3 was detected in routine histology. In other case both @entity1600 and routine histology were negative, but @entity3 was detected in non- @entity1600 (level VI) neck dissection. The overall accuracy of the @entity1600 biopsy was 91.3%, positive predictive value 100% and negative predictive value 81.8%. CONCLUSION: The results seem the @entity1600 biopsy technique is a feasible and valuable method for detecting cervical lymph node @entity3 and is helpful to decide performing neck dissection in @entity1 with cN0 @entity3557 .

title: [Sentinel lymph node biopsy in XXXX ].

entities_list: @entity3557 :: ('MESH:C536915', 'Disease') :: ['papillary thyroid carcinoma', 'thyroid papillary carcinoma']

entities_list: @entity1600 :: ('MESH:D014388', 'Disease') :: ['sentinel lymph node', 'SLN']

entities_list: @entity6693 :: ('MESH:D008751', 'Chemical') :: ['methylene blue', 'Methylene blue']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'Metastases']

answer: @entity3557 :: (MESH:C536915,Disease) :: ['papillary thyroid cancer']


abstract: OBJECTIVE: To assess the efficacy and safety of bevacizumab plus @entity2600 -based regimen for the first line treatment in metastatic @entity14 (mCRC) @entity1 , and to investigate the correlation between serum @entity5 markers including @entity787 and CA19-9 and response as well as prognosis. METHODS: From May 2007 to July 2008, 67 previously untreated mCRC @entity1 received treatment of IFL (n = 25), IFL plus Bevacizumab (n = 20) or FOLFIRI (n = 22). The treatment continued until disease progression or unacceptable @entity137 . The data were retrospectively analyzed. RESULTS: All @entity1 were evaluable for response, survival and @entity137 analysis. The objective response rate of IFL, IFL plus Bevacizumab or FOLFIRI regimen groups was 16.0% (4/25), 35.0% (7/20) and 18.2% (4/22), respectively (  (2) = 6.026, P = 0.049). The median progression-free survival (PFS) of IFL plus bevacizumab group was 7.5 months, significantly improved as compared with 3.7 months in the IFL group and 4 months in FOLFIRI group (  (2) = 11.97, P = 0.003). Of all 67 cases, the one-year survival rate was 47.0%, two-year survival rate was 27.0%, and the median overall survival (OS) was 13.0 months, with no significant difference among the three treatment groups (  (2) = 3.42, P = 0.18). The serum @entity787 and CA19-9 levels were decreased after treatment, but with no significant difference among the three groups (P > 0.05). The common @entity137 profiles of IFL and FOLFIRI regimens were @entity294 and @entity1398 , while the @entity137 related to bevacizumab was consistent with that documented in previous literature, such as @entity101 , @entity548 , @entity1370 and delayed wound @entity446 . CONCLUSION: The addition of bevacizumab to @entity2600 -based regimen significantly improves the response rate and PFS in first-line treatment for @entity1 with mCRC and its @entity137 is well tolerated.

title: [Evaluation of bevacizumab combined with XXXX -based regimen as the first-line treatment for @entity1 with metastatic @entity14 ].

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

entities_list: @entity1370 :: ('MESH:D066126', 'Disease') :: ['cardiac toxicity']

answer: @entity2600 :: (MESH:C051890,Chemical) :: ['irinotecan']


abstract: OBJECTIVE: To assess the efficacy and safety of bevacizumab plus @entity2600 -based regimen for the first line treatment in metastatic @entity14 (mCRC) @entity1 , and to investigate the correlation between serum @entity5 markers including @entity787 and CA19-9 and response as well as prognosis. METHODS: From May 2007 to July 2008, 67 previously untreated mCRC @entity1 received treatment of IFL (n = 25), IFL plus Bevacizumab (n = 20) or FOLFIRI (n = 22). The treatment continued until disease progression or unacceptable @entity137 . The data were retrospectively analyzed. RESULTS: All @entity1 were evaluable for response, survival and @entity137 analysis. The objective response rate of IFL, IFL plus Bevacizumab or FOLFIRI regimen groups was 16.0% (4/25), 35.0% (7/20) and 18.2% (4/22), respectively (  (2) = 6.026, P = 0.049). The median progression-free survival (PFS) of IFL plus bevacizumab group was 7.5 months, significantly improved as compared with 3.7 months in the IFL group and 4 months in FOLFIRI group (  (2) = 11.97, P = 0.003). Of all 67 cases, the one-year survival rate was 47.0%, two-year survival rate was 27.0%, and the median overall survival (OS) was 13.0 months, with no significant difference among the three treatment groups (  (2) = 3.42, P = 0.18). The serum @entity787 and CA19-9 levels were decreased after treatment, but with no significant difference among the three groups (P > 0.05). The common @entity137 profiles of IFL and FOLFIRI regimens were @entity294 and @entity1398 , while the @entity137 related to bevacizumab was consistent with that documented in previous literature, such as @entity101 , @entity548 , @entity1370 and delayed wound @entity446 . CONCLUSION: The addition of bevacizumab to @entity2600 -based regimen significantly improves the response rate and PFS in first-line treatment for @entity1 with mCRC and its @entity137 is well tolerated.

title: [Evaluation of bevacizumab combined with @entity2600 -based regimen as the first-line treatment for @entity1 with metastatic XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']


abstract: OBJECTIVE: To assess the efficacy and safety of bevacizumab plus @entity2600 -based regimen for the first line treatment in metastatic @entity14 (mCRC) @entity1 , and to investigate the correlation between serum @entity5 markers including @entity787 and CA19-9 and response as well as prognosis. METHODS: From May 2007 to July 2008, 67 previously untreated mCRC @entity1 received treatment of IFL (n = 25), IFL plus Bevacizumab (n = 20) or FOLFIRI (n = 22). The treatment continued until disease progression or unacceptable @entity137 . The data were retrospectively analyzed. RESULTS: All @entity1 were evaluable for response, survival and @entity137 analysis. The objective response rate of IFL, IFL plus Bevacizumab or FOLFIRI regimen groups was 16.0% (4/25), 35.0% (7/20) and 18.2% (4/22), respectively (  (2) = 6.026, P = 0.049). The median progression-free survival (PFS) of IFL plus bevacizumab group was 7.5 months, significantly improved as compared with 3.7 months in the IFL group and 4 months in FOLFIRI group (  (2) = 11.97, P = 0.003). Of all 67 cases, the one-year survival rate was 47.0%, two-year survival rate was 27.0%, and the median overall survival (OS) was 13.0 months, with no significant difference among the three treatment groups (  (2) = 3.42, P = 0.18). The serum @entity787 and CA19-9 levels were decreased after treatment, but with no significant difference among the three groups (P > 0.05). The common @entity137 profiles of IFL and FOLFIRI regimens were @entity294 and @entity1398 , while the @entity137 related to bevacizumab was consistent with that documented in previous literature, such as @entity101 , @entity548 , @entity1370 and delayed wound @entity446 . CONCLUSION: The addition of bevacizumab to @entity2600 -based regimen significantly improves the response rate and PFS in first-line treatment for @entity1 with mCRC and its @entity137 is well tolerated.

title: [Evaluation of bevacizumab combined with @entity2600 -based regimen as the first-line treatment for XXXX with metastatic @entity14 ].

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: To analyze the clinicopathologic characteristics of @entity995 spontaneous regression. METHODS: Retrospective case series study. The clinic and pathologic data of 52 cases of @entity995 spontaneous regression were analyzed retrospectively. All the cases came from 579 cases of @entity995 (without pre-enucleation chemotherapy) archived in Ophthalmic Pathology Laboratory of Beijing Tongren Eye Centre from Jan. 2007 to Dec. 2013. The analyzed factors included @entity5 activity, @entity5 invasion, and tissue changes of uveal and lens. RESULTS: In this study, the @entity1 ' average age was (14.0    8.7) months. There were 33 (63.5%) male and 19 (36.5%) female @entity1 . The rate of @entity995 spontaneous regression was 9.0% (52/579), of which the rate of complete regression was 1.4% (8/579). The most common symptom was leucocoria coupled with red eye 55.8% (29/52). The typical clinicopathologic characteristics were as follows: (1) all or most of all @entity5 cells @entity39 and only @entity5 cell remains were left; (2)most eyeballs showed atrophiabulbi or phthisis bulbi; (3) severe @entity194 occurred in @entity2184 , especially in iris and ciliary body combined with pigment cells disintegrating; (4) @entity231 formed coupled with @entity4 , displacement, or wrapped by fibrous connective tissue; (5) in a small number of cases, there were alive @entity5 cells in the retrolaminar optic nerve or choroid in spite of most @entity5 cells had suffered regression, indicating the @entity1 had histopathologic high risk factors and had the dispositions of @entity5 diffusion and @entity3 . CONCLUSIONS: Some untypical clinical manifestation such as leukocoria coupled with red eye or @entity5066 bulbi should be paid close attention. The possibility of @entity995 spontaneous regression should be considered. Meanwhile, some cases of @entity995 spontaneous regression with histopathologic high risk factors should be given post-enucleation systemic adjuvant chemotherapy combined with close observations and follow-ups.

title: [ XXXX spontaneous regression: clinical and histopathologic analysis].

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['suffered coagulation necrosis']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['lens swelling']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity995 :: ('MESH:D012175', 'Disease') :: ['retinoblastoma']

answer: @entity995 :: (MESH:D012175,Disease) :: ['Retinoblastoma']


abstract: Intrathecal injection of @entity10813 produced dual effects on sensory and motor functions in the spinal cord of the @entity35 . At a dose of 5 nmol, @entity10813 produced an increase in tail flick latency (TFL) as well as a reversible motor @entity912 as assessed by change in the angle of inclined plane. At a dose of 10 or 20 nmol, dynorphin produced a motor @entity912 lasting for up to 24 hours. The effect of @entity10813 on the sensory function of the spinal cord was shown by an increase in the vocalization threshold induced by electrical stimulation of the tail, at dose range of 1.25-10 nmol, with a quick onset (5 min) and relatively short duration (within 60 min). Unlike tail flick reaction which involves spinal motor function, tail stimulation-induced vocalization threshold is a relatively pure index for spinal nociceptive activities. The differential effect of dynorphin on sensory and motor function was supported by the evidence that (1) dynorphin-induced analgesic effect (increase in vocalization threshold) was @entity1510 reversible, whereas @entity10813 -induced motor @entity912 was naloxone resistant. (2) Nor-BNI, a specific antagonist for kappa opioid receptor, blocked the sensory effect of dynorphin, but had no influence on motor effect of dynorphin. It is thus concluded that dynorphin has both analgesic and paralytic effects in spinal cord. The @entity1337 shown by an increase of vocalization threshold is an opioid effect, most probably mediated by kappa opioid receptor; the paralytic effect, however, is a non-opioid effect. The increase of TFL induced by dynorphin involves both sensory ( @entity1337 ) and motor ( @entity912 ) effects.

title: Comparative study of the analgesic and paralytic effects induced by intrathecal XXXX in @entity35 .

entities_list: @entity1337 :: ('MESH:D000699', 'Disease') :: ['analgesia']

entities_list: @entity1510 :: ('MESH:D009270', 'Chemical') :: ['naloxone']

entities_list: @entity10813 :: ('MESH:D004399', 'Chemical') :: ['dynorphin', 'dynorphin A']

entities_list: @entity912 :: ('MESH:D010243', 'Disease') :: ['paralysis']

answer: @entity10813 :: (MESH:D004399,Chemical) :: ['dynorphin a']


abstract: Intrathecal injection of @entity10813 produced dual effects on sensory and motor functions in the spinal cord of the @entity35 . At a dose of 5 nmol, @entity10813 produced an increase in tail flick latency (TFL) as well as a reversible motor @entity912 as assessed by change in the angle of inclined plane. At a dose of 10 or 20 nmol, dynorphin produced a motor @entity912 lasting for up to 24 hours. The effect of @entity10813 on the sensory function of the spinal cord was shown by an increase in the vocalization threshold induced by electrical stimulation of the tail, at dose range of 1.25-10 nmol, with a quick onset (5 min) and relatively short duration (within 60 min). Unlike tail flick reaction which involves spinal motor function, tail stimulation-induced vocalization threshold is a relatively pure index for spinal nociceptive activities. The differential effect of dynorphin on sensory and motor function was supported by the evidence that (1) dynorphin-induced analgesic effect (increase in vocalization threshold) was @entity1510 reversible, whereas @entity10813 -induced motor @entity912 was naloxone resistant. (2) Nor-BNI, a specific antagonist for kappa opioid receptor, blocked the sensory effect of dynorphin, but had no influence on motor effect of dynorphin. It is thus concluded that dynorphin has both analgesic and paralytic effects in spinal cord. The @entity1337 shown by an increase of vocalization threshold is an opioid effect, most probably mediated by kappa opioid receptor; the paralytic effect, however, is a non-opioid effect. The increase of TFL induced by dynorphin involves both sensory ( @entity1337 ) and motor ( @entity912 ) effects.

title: Comparative study of the analgesic and paralytic effects induced by intrathecal @entity10813 in XXXX .

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: UNASSIGNED: @entity195 ( @entity195 ) is the most prevalent form of @entity179 characterized by neuritic plaques containing amyloid-b peptide (Ab) and @entity3072 . Evidence has been reported that Ab1-42 plays an essential pathogenic role in decreased spine density, impairment of synaptic plasticity, and @entity528 with disruption of memory-related synapse function, all associated with @entity195 . Experimentally, Ab1-42 oligomers perturb hippocampal long-term potentiation (LTP), an electrophysiological correlate of learning and memory. Ab was also reported to perturb synaptic @entity2227 ( @entity367 )-recycling by inhibiting excitatory- @entity535 -transporters. Elevated level of extracellular @entity367 leads to activation of perisynaptic receptors, including @entity13069 subunit containing NMDARs. These receptors were shown to induce impaired LTP and enhanced long-term @entity308 and proapoptotic pathways, all central features of @entity195 . In the present study, we investigated the role of @entity367 -recycling on Ab1-42-induced LTP deficit in the @entity1399 . We found that Ab-induced @entity16 , which was mimicked by the @entity367 -reuptake inhibitor TBOA, could be rescued by blocking the @entity13069 subunit of @entity143 receptors. Furthermore, decreasing the level of extracellular @entity367 using a @entity367 scavenger also restores TBOA or Ab induces @entity16 . Overall, these results suggest that reducing ambient @entity367 in the brain can be protective against Ab-induced synaptic disruption.

title: Amyloid-b1-42 Disrupts Synaptic Plasticity by Altering XXXX Recycling at the Synapse.

entities_list: @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino-acid']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['LTP damage']

entities_list: @entity3072 :: ('MESH:C536599', 'Disease') :: ['neurofibrillary tangles']

entities_list: @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegenerative disorders']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's disease"]

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal loss']

answer: @entity2227 :: (CHEBI:29987,Chemical) :: ['Glutamate']


abstract: The non-steroidal anti-inflammatory drug (NSAID) @entity7988 ( @entity7988 ) is used as intravenous monotherapy incorporated in 0.9% normal saline solution (100 mg @entity7988 ampoule + 200 ml normal saline) in the treatment of renal colic. We present our experience in 65 @entity1 complaining of clinically diagnosed renal colic who were treated by intravenous saline- @entity7988 . Prospective investigations revaled urinary calculi in 51 @entity1 , @entity5201 (crystalluria) in 5, acute @entity1960 in 2, severe @entity5442 in 2, negative investigations in 3 and @entity614 in 2 @entity1 . Positive response was observed in 93.8% of @entity1 as far as @entity158 relief is concerned. @entity158 relief started within 5-7 minutes after beginning the infusion. Duration of analgesic effect ranged between 4 and 12 hours. Repeating the injection was done for maintenance of @entity1337 . Side effects included @entity1605 @entity1 , palpitation in 1 @entity1 , @entity158 in 1, muscular @entity14695 in 1 @entity1 . @entity7988 , an antiprostaglandin, is a powerful anti-inflammatory and potent analgesic. Intravenous saline- @entity7988 is a good emergency treatment for @entity810 .

title: Emergency treatment of renal colic with intravenous XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity7988 :: ('MESH:D007660', 'Chemical') :: ['Ketoprofen', 'Profenid']

entities_list: @entity1605 :: ('OMIM:217000', 'Disease') :: ['drowsiness in 2']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['Pain', 'pain', 'epigastric pain']

entities_list: @entity810 :: ('MESH:D058186', 'Disease') :: ['acute episodes of renal colic']

entities_list: @entity614 :: ('MESH:D011843', 'Disease') :: ['radiculitis']

answer: @entity7988 :: (MESH:D007660,Chemical) :: ['ketoprofen']


abstract: A 34-year-old @entity1 who was 20 weeks pregnant developed @entity6794 while receiving treatment for @entity1188 . Because of her septic condition an abortion was performed. The @entity1 received intravenous @entity617 as a pulse treatment for her @entity6794 , which was followed by oral @entity1667 and oral @entity3761 for 6 weeks. After dose reduction the @entity1 had a severe relapse. The @entity134 dose was increased and @entity3761 was replaced by @entity205 . The smaller ulcers healed spontaneously, but skin grafting had to be performed for the large @entity1066 . The @entity134 therapy was tapered and discontinued. @entity205 was continued for 10 weeks as monotherapy. Subsequently, the @entity1 was free of symptoms for 7 months. Twelve months after the diagnosis of @entity6794 the @entity1 developed @entity3052 accompanied by a recurrence of the @entity272 .

title: [ XXXX as a precursor of myeloid leukemia].

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone']

entities_list: @entity6794 :: ('MESH:D017511', 'Disease') :: ['pyoderma gangrenosum']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukaemia']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporin A', 'Cyclosporin A']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct pneumonia']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['skin disease']

entities_list: @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']

answer: @entity6794 :: (MESH:D017511,Disease) :: ['Pyoderma gangrenosum']


abstract: To evaluate the significance of alterations in cell adhesion-related genes methylation during lung multistep @entity105 induced by the genotoxic carcinogens @entity5954 ( @entity9623 ) and @entity107 ( @entity108 ), tissue samples microdissected from @entity9623 / @entity108 -induced @entity35 lung @entity105 model were subjected to methylation-specific PCR to evaluate the DNA methylation status of @entity71960 , @entity11019 , @entity17937 and @entity17935 . Immunohistochemistry was used to determine protein expression of @entity71960 , @entity11019 , @entity17935 and the DNA methyltransferases (DNMTs) 1, 3a and 3b. @entity17937 hypermethylation was not detected in any tissue. @entity71960 , @entity11019 and @entity17935 hypermethylation was correlated with the loss of their protein expression during the progression of pathologic lesions. The prevalence of DNA methylation of at least one gene and the average number of methylated genes increased with the histological progression. @entity14923 and @entity54389 protein expression increased progressively during the stages of lung @entity105 , whereas @entity54390 overexpression was only found in several samples. Furthermore, @entity14923 protein expression levels were correlated with @entity71960 methylation, and @entity54389 protein expression levels were correlated with @entity71960 , @entity11019 and @entity17935 methylation. The average number of methylated genes during @entity105 was significantly correlated with @entity14923 and @entity54389 protein expression levels. Moreover, mRNA expression of @entity71960 significantly increased after treatment with DNMT inhibitor @entity11508 in @entity71960 -methylated @entity5 cell lines. Our findings suggest that an accumulation of hypermethylation accounts for cell adhesion-related gene silencing is associated with dynamic changes in the progression of @entity9623 / @entity108 -induced @entity35 lung @entity105 . We suggest that @entity14923 and @entity54389 protein overexpression may be responsible for this aberrant DNA methylation.

title: Aberrant methylation accounts for cell adhesion-related gene silencing during XXXX and @entity107 induced multistep @entity35 lung @entity105 associated with overexpression of @entity54389 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor']

entities_list: @entity107 :: ('MESH:D004052', 'Chemical') :: ['diethylnitrosamine']

entities_list: @entity5954 :: ('MESH:D008748', 'Chemical') :: ['3-methylcholanthrene']

entities_list: @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis']

entities_list: @entity11508 :: ('MESH:C014347', 'Chemical') :: ["5-aza-2'-deoxycytidine"]

answer: @entity5954 :: (MESH:D008748,Chemical) :: ['3-methylcholanthrene']


abstract: To evaluate the significance of alterations in cell adhesion-related genes methylation during lung multistep @entity105 induced by the genotoxic carcinogens @entity5954 ( @entity9623 ) and @entity107 ( @entity108 ), tissue samples microdissected from @entity9623 / @entity108 -induced @entity35 lung @entity105 model were subjected to methylation-specific PCR to evaluate the DNA methylation status of @entity71960 , @entity11019 , @entity17937 and @entity17935 . Immunohistochemistry was used to determine protein expression of @entity71960 , @entity11019 , @entity17935 and the DNA methyltransferases (DNMTs) 1, 3a and 3b. @entity17937 hypermethylation was not detected in any tissue. @entity71960 , @entity11019 and @entity17935 hypermethylation was correlated with the loss of their protein expression during the progression of pathologic lesions. The prevalence of DNA methylation of at least one gene and the average number of methylated genes increased with the histological progression. @entity14923 and @entity54389 protein expression increased progressively during the stages of lung @entity105 , whereas @entity54390 overexpression was only found in several samples. Furthermore, @entity14923 protein expression levels were correlated with @entity71960 methylation, and @entity54389 protein expression levels were correlated with @entity71960 , @entity11019 and @entity17935 methylation. The average number of methylated genes during @entity105 was significantly correlated with @entity14923 and @entity54389 protein expression levels. Moreover, mRNA expression of @entity71960 significantly increased after treatment with DNMT inhibitor @entity11508 in @entity71960 -methylated @entity5 cell lines. Our findings suggest that an accumulation of hypermethylation accounts for cell adhesion-related gene silencing is associated with dynamic changes in the progression of @entity9623 / @entity108 -induced @entity35 lung @entity105 . We suggest that @entity14923 and @entity54389 protein overexpression may be responsible for this aberrant DNA methylation.

title: Aberrant methylation accounts for cell adhesion-related gene silencing during @entity5954 and @entity107 induced multistep XXXX lung @entity105 associated with overexpression of @entity54389 .

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: To evaluate the significance of alterations in cell adhesion-related genes methylation during lung multistep @entity105 induced by the genotoxic carcinogens @entity5954 ( @entity9623 ) and @entity107 ( @entity108 ), tissue samples microdissected from @entity9623 / @entity108 -induced @entity35 lung @entity105 model were subjected to methylation-specific PCR to evaluate the DNA methylation status of @entity71960 , @entity11019 , @entity17937 and @entity17935 . Immunohistochemistry was used to determine protein expression of @entity71960 , @entity11019 , @entity17935 and the DNA methyltransferases (DNMTs) 1, 3a and 3b. @entity17937 hypermethylation was not detected in any tissue. @entity71960 , @entity11019 and @entity17935 hypermethylation was correlated with the loss of their protein expression during the progression of pathologic lesions. The prevalence of DNA methylation of at least one gene and the average number of methylated genes increased with the histological progression. @entity14923 and @entity54389 protein expression increased progressively during the stages of lung @entity105 , whereas @entity54390 overexpression was only found in several samples. Furthermore, @entity14923 protein expression levels were correlated with @entity71960 methylation, and @entity54389 protein expression levels were correlated with @entity71960 , @entity11019 and @entity17935 methylation. The average number of methylated genes during @entity105 was significantly correlated with @entity14923 and @entity54389 protein expression levels. Moreover, mRNA expression of @entity71960 significantly increased after treatment with DNMT inhibitor @entity11508 in @entity71960 -methylated @entity5 cell lines. Our findings suggest that an accumulation of hypermethylation accounts for cell adhesion-related gene silencing is associated with dynamic changes in the progression of @entity9623 / @entity108 -induced @entity35 lung @entity105 . We suggest that @entity14923 and @entity54389 protein overexpression may be responsible for this aberrant DNA methylation.

title: Aberrant methylation accounts for cell adhesion-related gene silencing during @entity5954 and @entity107 induced multistep @entity35 lung XXXX associated with overexpression of @entity54389 .

answer: @entity105 :: (MESH:D063646,Disease) :: ['carcinogenesis']


abstract: To evaluate the significance of alterations in cell adhesion-related genes methylation during lung multistep @entity105 induced by the genotoxic carcinogens @entity5954 ( @entity9623 ) and @entity107 ( @entity108 ), tissue samples microdissected from @entity9623 / @entity108 -induced @entity35 lung @entity105 model were subjected to methylation-specific PCR to evaluate the DNA methylation status of @entity71960 , @entity11019 , @entity17937 and @entity17935 . Immunohistochemistry was used to determine protein expression of @entity71960 , @entity11019 , @entity17935 and the DNA methyltransferases (DNMTs) 1, 3a and 3b. @entity17937 hypermethylation was not detected in any tissue. @entity71960 , @entity11019 and @entity17935 hypermethylation was correlated with the loss of their protein expression during the progression of pathologic lesions. The prevalence of DNA methylation of at least one gene and the average number of methylated genes increased with the histological progression. @entity14923 and @entity54389 protein expression increased progressively during the stages of lung @entity105 , whereas @entity54390 overexpression was only found in several samples. Furthermore, @entity14923 protein expression levels were correlated with @entity71960 methylation, and @entity54389 protein expression levels were correlated with @entity71960 , @entity11019 and @entity17935 methylation. The average number of methylated genes during @entity105 was significantly correlated with @entity14923 and @entity54389 protein expression levels. Moreover, mRNA expression of @entity71960 significantly increased after treatment with DNMT inhibitor @entity11508 in @entity71960 -methylated @entity5 cell lines. Our findings suggest that an accumulation of hypermethylation accounts for cell adhesion-related gene silencing is associated with dynamic changes in the progression of @entity9623 / @entity108 -induced @entity35 lung @entity105 . We suggest that @entity14923 and @entity54389 protein overexpression may be responsible for this aberrant DNA methylation.

title: Aberrant methylation accounts for cell adhesion-related gene silencing during @entity5954 and @entity107 induced multistep @entity35 lung @entity105 associated with overexpression of XXXX .

answer: @entity54389 :: (444984(Tax:10116),Gene) :: ['DNA methyltransferases 1 and 3a']


abstract: To evaluate the significance of alterations in cell adhesion-related genes methylation during lung multistep @entity105 induced by the genotoxic carcinogens @entity5954 ( @entity9623 ) and @entity107 ( @entity108 ), tissue samples microdissected from @entity9623 / @entity108 -induced @entity35 lung @entity105 model were subjected to methylation-specific PCR to evaluate the DNA methylation status of @entity71960 , @entity11019 , @entity17937 and @entity17935 . Immunohistochemistry was used to determine protein expression of @entity71960 , @entity11019 , @entity17935 and the DNA methyltransferases (DNMTs) 1, 3a and 3b. @entity17937 hypermethylation was not detected in any tissue. @entity71960 , @entity11019 and @entity17935 hypermethylation was correlated with the loss of their protein expression during the progression of pathologic lesions. The prevalence of DNA methylation of at least one gene and the average number of methylated genes increased with the histological progression. @entity14923 and @entity54389 protein expression increased progressively during the stages of lung @entity105 , whereas @entity54390 overexpression was only found in several samples. Furthermore, @entity14923 protein expression levels were correlated with @entity71960 methylation, and @entity54389 protein expression levels were correlated with @entity71960 , @entity11019 and @entity17935 methylation. The average number of methylated genes during @entity105 was significantly correlated with @entity14923 and @entity54389 protein expression levels. Moreover, mRNA expression of @entity71960 significantly increased after treatment with DNMT inhibitor @entity11508 in @entity71960 -methylated @entity5 cell lines. Our findings suggest that an accumulation of hypermethylation accounts for cell adhesion-related gene silencing is associated with dynamic changes in the progression of @entity9623 / @entity108 -induced @entity35 lung @entity105 . We suggest that @entity14923 and @entity54389 protein overexpression may be responsible for this aberrant DNA methylation.

title: Aberrant methylation accounts for cell adhesion-related gene silencing during @entity5954 and XXXX induced multistep @entity35 lung @entity105 associated with overexpression of @entity54389 .

answer: @entity107 :: (MESH:D004052,Chemical) :: ['diethylnitrosamine']


abstract: Background: Current sedation guidelines recommend avoiding @entity1245 but express no preference for @entity1875 versus @entity6948 . In addition, there are limited data on how well randomized controlled trials on sedatives generalize to routine practice where conditions tend to be more varied and complex. Methods: We gathered daily sedative exposure data from all @entity1 on mechanical ventilation for >= 3 days over a 7-year period in a large academic medical center. We compared hazard ratios for ventilator-associated events (VAEs), extubation, hospital discharge, and @entity204 amongst @entity1245 , @entity1875 , and @entity6948 using proportional subdistribution hazard models with competing risks. We adjusted all analyses for ICU type, demographics, comorbidities, procedures, severity of @entity221 , @entity551 , oxygenation, renal function, opioids, neuroleptics, neuromuscular blockers, awakening and breathing trials, and calendar year. Results: We evaluated 9,603 consecutive episodes of mechanical ventilation. @entity1245 and @entity1875 were associated with increased VAE risk whereas @entity6948 was not. @entity1875 was associated with less time to extubation compared to @entity1245 (HR for extubation 1.4, 95% CI 1.3-1.5). @entity6948 was associated with less time to extubation compared to both @entity1245 (HR 2.3, 95% CI 2.0-2.7) and @entity1875 (HR 1.7, 95% CI 1.4-2.0) but there were relatively few @entity6948 exposures available for analysis. There were no differences between any two agents in hazards for hospital discharge or mortality. Conclusions: In this large, real-world cohort, @entity1875 and @entity6948 were associated with less time to extubation compared to @entity1245 but @entity6948 was also associated with less time to extubation compared to @entity1875 . These possible differences merit further study.

title: Associations between different sedatives and ventilator-associated events, length-of-stay, and mortality in mechanically ventilated XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

entities_list: @entity1245 :: ('MESH:D001569', 'Chemical') :: ['Benzodiazepines', 'benzodiazepines']

entities_list: @entity1875 :: ('MESH:D015742', 'Chemical') :: ['propofol', 'Propofol']

entities_list: @entity6948 :: ('MESH:D020927', 'Chemical') :: ['dexmedetomidine', 'Dexmedetomidine']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['hospital death']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: PURPOSE: To determine if postoperative external pelvic radiation (EBRT), without vaginal brachytherapy, is sufficient to prevent vaginal cuff and pelvic recurrences in @entity1 with surgical Stage I @entity1204 ( @entity420 ). METHODS AND MATERIALS: The records of 122 @entity1 with surgical @entity1204 were reviewed. There were 87 @entity1 with @entity420 who received EBRT alone and are the subject of this study. Their radiation records were reviewed. All @entity1 underwent exploration, total abdominal hysterectomy, and bilateral salpingo-oophorectomy (TAH BSO), and pelvic and paraaortic lymph node sampling. They were staged according to the FIGO 1988 surgical staging system recommendations. Postoperatively, pelvic EBRT was administered by megavoltage equipment using four fields, to a total dose of 45 to 50.4 Gy. Actuarial survival and disease free survival were calculated according to Kaplan-Meier Method. RESULTS: Twenty-seven @entity1 with Stage IA Grade 1 or 2 @entity420 with less than one-third myometrial invasion, who did not receive EBRT, and eight @entity1 with histology other than @entity420 (i.e., serous papillary, mucinous, etc.) were not included in the study. For the remaining 87 @entity1 who are in the study group, the median follow-up was 52 months (range: 12-82 months). The 5-year overall survival for these 87 @entity1 was 92%, with a disease-free survival of 83%. There were no @entity5 recurrences in the upper vagina or in the pelvis. Two @entity1 developed @entity1744 (no surgery required), and one @entity1 developed @entity102 . CONCLUSION: Adjuvant external pelvic radiation, without vaginal brachytherapy, prevents pelvic and vaginal cuff recurrences in surgical Stage I endometrial @entity420 .

title: Pelvic control following external beam radiation for surgical stage I XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1204 :: ('MESH:D016889', 'Disease') :: ['Stage I endometrial cancer', 'endometrial adenocarcinoma']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic enteritis']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['ACA', 'adenocarcinoma']

entities_list: @entity1744 :: ('MESH:D043183', 'Disease') :: ['small bowel obstruction']

answer: @entity1204 :: (MESH:D016889,Disease) :: ['endometrial adenocarcinoma']


abstract: @entity565 is a disease of the lung epithelial barrier, most often associated with @entity566 in @entity1 . @entity565 and @entity566 are two distinct diseases, but the phenotypic expression of @entity565 depends on atopic status. A better definition of phenotypes of @entity565 would result in better targeting of prevention and treatment modalities. Secondary prevention aims to prevent the onset of @entity565 and the acquisition of new sensitizations in sensitized @entity1 . Studies concerning allergen avoidance are insufficient to reach a definitive conclusion and antihistamines have not been shown to be effective. The results for specific immunotherapy suggest a benefit to prevent transition from @entity2023 to @entity565 and the onset of new sensitizations. Tertiary prevention aims to reduce symptoms in @entity1 with an existing @entity56 diagnosis. The avoidance of known @entity1576 will only be effective in combination with management of the whole environment. Specific immunotherapy has a real place, in combination with background therapy. It should be used according to guidelines in appropriately treated @entity1 .

title: [Secondary and tertiary prevention of XXXX in @entity1 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity2023 :: ('MESH:D006255', 'Disease') :: ['allergic rhinitis']

entities_list: @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma', 'Asthma']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic asthma']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory allergens']

answer: @entity56 :: (MESH:D004342,Disease) :: ['allergic asthma']


abstract: @entity565 is a disease of the lung epithelial barrier, most often associated with @entity566 in @entity1 . @entity565 and @entity566 are two distinct diseases, but the phenotypic expression of @entity565 depends on atopic status. A better definition of phenotypes of @entity565 would result in better targeting of prevention and treatment modalities. Secondary prevention aims to prevent the onset of @entity565 and the acquisition of new sensitizations in sensitized @entity1 . Studies concerning allergen avoidance are insufficient to reach a definitive conclusion and antihistamines have not been shown to be effective. The results for specific immunotherapy suggest a benefit to prevent transition from @entity2023 to @entity565 and the onset of new sensitizations. Tertiary prevention aims to reduce symptoms in @entity1 with an existing @entity56 diagnosis. The avoidance of known @entity1576 will only be effective in combination with management of the whole environment. Specific immunotherapy has a real place, in combination with background therapy. It should be used according to guidelines in appropriately treated @entity1 .

title: [Secondary and tertiary prevention of @entity56 in XXXX ].

answer: @entity1 :: (9606,Species) :: ['children']


abstract: The term smooth uterine muscle of uncertain malignant potential (STUMPs) indicates a group of uterine smooth @entity11090 (SMTs) that cannot be diagnosed unequivocally as benign or malignant. Diagnosis, surgical management, and follow-up of this @entity5 remain controversial, especially in pre-menopausal @entity1 with fertility desire, due to the @entity146 and prolonged survival rate when compared to @entity1822 . However, recurrence is estimated between 8.7% and 11% and may include delayed-recurrences. We reported five cases of uterine masses treated by surgical procedure diagnosed as STUMP on final pathology. Four @entity1 underwent a total abdominal hysterectomy with or without salpingo-oophorectomy. One @entity1 underwent excision of uterine mass and subsequent total abdominal hysterectomy plus bilateral salpingo-oophorectomy after the diagnosis of STUMP. All @entity1 in our study remained recurrence-free to date (with a follow up period ranging from 6 to 81 months). Based on our experience and in consideration of the lack of consensus regarding the malignant potential, diagnostic criteria, gold-standard treatment and follow-up, we believe that close multidisciplinary management is mandatory in the event of STUMP. We suggest that gynaecologist, dedicated pathologist (with high level of expertize in gynaecological pathology) and oncologist should work as a team in the counselling and management of this @entity5 from detection till completion of follow up. Furthermore, we recommend immunohistochemistry to investigate the overexpression of @entity986 and @entity876 in order to identify the cohort of @entity1 at increased risk of recurrence who may benefit from more aggressive surgical-oncological strategies.

title: Uterine smooth XXXX of uncertain malignant potential (STUMP): pathology, follow-up and recurrence.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['non aggressive behaviour']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasm']

entities_list: @entity1822 :: ('MESH:D007890', 'Disease') :: ['leiomyosarcomas']

entities_list: @entity11090 :: ('MESH:D019042', 'Disease') :: ['muscle tumors']

answer: @entity11090 :: (MESH:D019042,Disease) :: ['muscle tumors']


abstract: Nowadays, advanced @entity1149 is still an incurable disease. Recent researches have led to considerable progress in the treatment of @entity1149 . This article reviews the main studies on chemotherapy on @entity1149 and discusses the new therapeutic strategies available to date. @entity66 ( @entity66 ) is necessary in chemotherapy for @entity5 . The proportion of population with responders or @entity66 basically maintained similar regardless of regimens. The overall survival after chemotherapy for @entity1 with @entity66 was lower than @entity1 with responders, and higher than @entity1 with progressive disease. Greater benefits could be achieved in @entity1 with effective induction chemotherapy using chemotherapeutic agents for maintenance therapy, whereas the benefits were relatively small for @entity1 with @entity66 . It has been found that @entity470 ( @entity470 ) mutation status had certain correlation with the efficacy of chemotherapy. First-line chemotherapy has shown advantages in effective rate and progression free survival on @entity470 mutant. @entity470 mutation produced significant effects on the efficacy of postoperative adjuvant chemotherapy. @entity1 with @entity470 mutation had a higher effective rate than wild-type @entity470 @entity1 , and @entity1 with responders had a greater benefit in progression free survival from maintenance therapy. However, it is still necessary to carry out more careful and deeper studies and analyses on traditional cytotoxic chemotherapy, to further optimize cytotoxic chemotherapy and to use molecular targeted agents with different mechanisms.

title: Selection of chemotherapy for XXXX is facilitated by new therapeutic strategies.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Stable disease', 'SD']

entities_list: @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung cancer']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']


abstract: @entity292 ( @entity292 ) is associated with a variety of diseases, but in recent years it has most frequently been observed with @entity356 . The management of @entity5 lesions and optimal surgical treatment strategies remain controversial. In this study, we explore the clinical diagnosis and treatment of @entity292 by retrospectively analyzing the records of @entity292 @entity1 treated between August 2008 and February 2014. Three female @entity1 and one male @entity1 with an average age of 61 years were diagnosed with @entity292 caused by @entity5 during this period. The predominant symptoms were @entity294 , @entity391 , @entity353 , and @entity490 . Gastrointestinal contrast series combined with fiber endoscopy was the most accurate method of diagnosing the @entity292 , while CT and MRI were helpful in identifying the extent of @entity5 invasion and evaluating the possibility of en-bloc resection. Pathological and immunohistochemical tests, including staining for @entity2225 , CK-7, and @entity6628 , suggested that three cases originated in the colon and one case in the stomach. All four cases underwent single-stage en-bloc fistula resection; two severely malnourished @entity1 received concurrent colostomies. One @entity1 died of postoperative @entity834 and @entity177 , but the remaining three @entity1 were discharged in improved condition. En-bloc resection followed by adjuvant chemotherapy can result in long term survival. Gastrointestinal contrast series combined with fiber endoscopy showed high sensitivity in the diagnosis of @entity292 . Immunohistochemical staining can be conducted for @entity5 with an unclear source. Single-stage radical en-bloc fistula resection is the recommended surgical treatment, and concurrent colostomy should be considered in severely malnourished @entity1 .

title: Current diagnosis and management of XXXX : a single surgical unit's experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity834 :: ('MESH:D057868', 'Disease') :: ['anastomotic leakage']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumor', 'malignancy', 'tumors']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['cardiopulmonary failure']

entities_list: @entity292 :: ('MESH:D005402', 'Disease') :: ['Gastrocolic fistula', 'GCF']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric or colonic malignancy']

answer: @entity5 :: (MESH:D009369,Disease) :: ['malignant gastrocolic fistulas']


abstract: OBJECTIVE: The aim of study was to examine the relationship between the dietary nutrition and the prevalence and risk of @entity8 in @entity1 with @entity209 . METHODS: 260 @entity1 with @entity209 and @entity740 meeting criterion were recruited in this cross-sectional study. @entity209 was defined according to NCEP-ATPIII guidelines. Food-frequency questionnaire was performed to collect the information on dietary nutrition. Anthropometric measurements, including body weight, height and waist circumference were collected. Blood pressure, @entity412 , @entity165 , high density lipoprotein- @entity165 and fasting plasma @entity413 , renal function and 24-hour urine protein were measured. The correlations between GFR and actual nutrient intakes of @entity1 were examined. RESULTS: The actual intakes of energy, @entity3363 , protein, fat and @entity165 in participate were all significantly higher than recommended nutrient intakes/adequate intakes of Chinese Dietary Reference Intakes. GFR was significantly inversely correlated with energy, protein intake, @entity165 intake, @entity3363 intake, @entity1372 intake, @entity460 intake and actual protein/energy ratio. Logistic regression analyses showed that actual protein intakes/recommended protein intakes (APIs/RPIs) were significant independent predictors of GFR < 60 ml/min   1.73 m(2). CONCLUSIONS: Dietary nutrition is closely correlated with @entity8 in @entity1 with @entity209 . High protein intakes may be one of the risk factors of @entity8 .

title: Association between the dietary factors and @entity209 with XXXX in Chinese adults.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['kidney damage', 'renal damage']

entities_list: @entity3363 :: ('MESH:D002241', 'Chemical') :: ['carbohydrates']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic renal disease']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['Metabolic syndrome', 'metabolic syndrome']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity740 :: (MESH:D051436,Disease) :: ['chronic kidney disease']


abstract: OBJECTIVE: The aim of study was to examine the relationship between the dietary nutrition and the prevalence and risk of @entity8 in @entity1 with @entity209 . METHODS: 260 @entity1 with @entity209 and @entity740 meeting criterion were recruited in this cross-sectional study. @entity209 was defined according to NCEP-ATPIII guidelines. Food-frequency questionnaire was performed to collect the information on dietary nutrition. Anthropometric measurements, including body weight, height and waist circumference were collected. Blood pressure, @entity412 , @entity165 , high density lipoprotein- @entity165 and fasting plasma @entity413 , renal function and 24-hour urine protein were measured. The correlations between GFR and actual nutrient intakes of @entity1 were examined. RESULTS: The actual intakes of energy, @entity3363 , protein, fat and @entity165 in participate were all significantly higher than recommended nutrient intakes/adequate intakes of Chinese Dietary Reference Intakes. GFR was significantly inversely correlated with energy, protein intake, @entity165 intake, @entity3363 intake, @entity1372 intake, @entity460 intake and actual protein/energy ratio. Logistic regression analyses showed that actual protein intakes/recommended protein intakes (APIs/RPIs) were significant independent predictors of GFR < 60 ml/min   1.73 m(2). CONCLUSIONS: Dietary nutrition is closely correlated with @entity8 in @entity1 with @entity209 . High protein intakes may be one of the risk factors of @entity8 .

title: Association between the dietary factors and XXXX with @entity740 in Chinese adults.

answer: @entity209 :: (MESH:D008659,Disease) :: ['metabolic syndrome']


abstract: OBJECTIVE: Stent placement for @entity4522 has become an alternative treatment technique; however, stent placement for @entity2500 remains a technical and clinical challenge. Our purpose was to assess the safety and feasibility of Wingspan stent for @entity1 with symptomatic M1 @entity850 , and its initial effect on prevention of @entity63 events. METHODS: Fifty-three cases with recurrent @entity2500 resistant to medical therapy treated by self-expanding stent were reviewed retrospectively (average 58  18.5 years old, 19 @entity1 ). All @entity1 underwent angioplasty and stenting with the Gateway @entity661 , and advised follow-up with DSA or @entity12705 at 6th month. RESULTS: @entity1 had an average @entity850 ratio of 76.5  15.4% prior to the treatment. Of the 53 @entity1 , the technical success rate was 98.1% as a whole (52/53). The mean degree of @entity850 reduced from (76.5  15.4)% to (18.2  11.3)%. Complications associated with the procedure include @entity510 (1.89%) and occlusion (3.78%) occurred. During a follow-up of 6 months, there was no recurrence of transient @entity63 attack or @entity64 in 52 cases with successful stenting. Cerebral hemodynamics of MCA using transcranial Doppler monitoring were at normal level (<120 cm/s) in 41 follow-up @entity1 . The follow up angiography at 6 month post-procedure was conducted in 32 @entity1 and showed good patency in stented vessels. CONCLUSIONS: Wingspan stent for symptomatic @entity850 of middle cerebral artery is a safe and feasible procedure. It improves clinical outcome in the intermediate follow up, but its long-term effect remains to be further evaluated.

title: Wingspan stent for symptomatic M1 XXXX of middle cerebral artery.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity2500 :: ('MESH:D020244', 'Disease') :: ['symptomatic MCA stenosis', 'middle cerebral artery (MCA) stenosis']

entities_list: @entity510 :: ('MESH:D013345', 'Disease') :: ['subarachnoid hemorrhage']

entities_list: @entity661 :: ('MESH:D054549', 'Disease') :: ['balloon-Wingspan stent system']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity4522 :: ('MESH:D002537', 'Disease') :: ['intracranial atherosclerotic stenosis']

answer: @entity850 :: (MESH:D003251,Disease) :: ['stenosis']


abstract: OBJECTIVE: Disparities in limb salvage procedures may be driven by @entity159 ( @entity159 ) and access to high-volume hospitals. We sought to identify @entity159 factors associated with major amputation in the setting of @entity63 ( @entity63 ). METHODS: The 2003-2007 Nationwide Inpatient Sample was queried for discharges containing lower extremity revascularization (LER) or major amputation and chronic @entity63 (N = 958,120). The Elixhauser method was used to adjust for comorbidities. Significant predictors in bivariate logistic regression were entered into a multivariate logistic regression for the dependent variable of amputation vs LER. RESULTS: Overall, 24.2% of @entity63 @entity1 underwent amputation. Significant differences were seen between both groups in bivariate and multivariate analysis of @entity159 factors, including race, income, and insurance status. @entity7881 @entity1 were more likely to be treated at low-LER-volume institutions (odds ratio [OR], 1.74; P < .001). @entity1 at higher-LER-volume centers (OR, 15.16; P <.001) admitted electively (OR, 2.19; P < .001) and evaluated with diagnostic imaging (OR, 10.63; P < .001) were more likely to receive LER. CONCLUSIONS: After controlling for comorbidities, minority @entity1 , those with lower @entity159 , and @entity1 with Medicaid were more likely receive amputation for @entity63 in low-volume hospitals. Addressing @entity159 and hospital factors may reduce amputation rates for @entity63 .

title: Socioeconomic and hospital-related predictors of amputation for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity7881 :: ('MESH:C563621', 'Disease') :: ['Lower-income']

entities_list: @entity159 :: ('MESH:D013226', 'Disease') :: ['SES', 'socioeconomic status']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['critical limb ischemia', 'CLI']

answer: @entity63 :: (MESH:D007511,Disease) :: ['critical limb ischemia']


abstract: Two experiments were conducted to evaluate the effects of dietary fat supplementation and a synthetic progestogen on metabolic hormone patterns and(or) in vitro and in vivo characteristics of induced corpora lutea (CL) in undernourished, post-partum beef @entity291 . Metabolizable energy intake was restricted in all @entity291 in both experiments before calving to achieve a body condition (BC) score of 4 (thin), with @entity291 fed to maintain BW and condition after calving. In Exp. 1, 16 @entity291 were fed isocaloric and isonitrogenous diets after calving with either no added fat (NL, n = 8) or added fat ( @entity1733 , n = 8; .374 kg of fat/500 kg BW). In Exp. 2, 32 pluriparous @entity291 that had reached targeted body condition were divided randomly at calving into a 2 x 2 factorial treatment arrangement: 1) @entity1733 -no implant; @entity1733 -CON, 2) @entity1733 -norgestomet implant d 14 to 21; @entity1733 -NORG, 3) NL-CON and, 4) NL-NORG. Forty-eight-hour @entity291 removal on d 21 and @entity1176 on d 23 were used to induce CL. The @entity1733 diet increased (P < .03) serum growth hormone (GH) concentrations, changed the puerperal pattern of serum insulin from cubic (P < .05) to linear (P < .05), and increased (P < .01) the in vitro production of @entity4208 by luteal tissue (Exp. 1). In Exp. 2, both @entity1733 diets and NORG treatments ( @entity1733 -NORG, @entity1733 -CON, NL NORG) tended to promote an increased (P < .09) frequency of luteal activity after @entity1176 , but only @entity1733 -CON and NL-NORG enhanced (P < .04) luteal lifespan.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Metabolic and luteal sequelae to heightened dietary fat intake in undernourished, anestrous beef XXXX induced to ovulate.

answer: @entity291 :: (9913,Species) :: ['cows']


abstract: The transcriptome is the mRNA pool found within a cell. Transcriptomic discovery approaches include microarray-based technologies as well as sequencing-based technologies. Transcriptomic experiments provide dynamic information about gene expression at the tissue level. The proteome is the pool of proteins expressed at a given time and circumstance. The word PROTEOMICS summarizes several technologies for visualization, quantitation, and identification of these proteins. Protein separation can be accomplished by two-dimensional electrophoresis, use of protein chips with an affinity matrix, or by a variety of advanced chromatographic methods. Mass spectrometry is used to identify the proteins in conjunction with protein sequence databases. Recent proteomic experiments in resting and activated platelets have identified novel signaling pathways and secreted proteins. Platelet transcriptomic studies in essential @entity1148 , @entity731 , @entity3458 , and an inherited @entity1423 are reviewed. Transcript profiling has the potential to distinguish molecular signatures in normal and diseased platelets and to classify prothrombotic @entity1 phenotypes to tailor their therapy.

title: Genomic and proteomic applications in diagnosis of XXXX and classification.

entities_list: @entity1148 :: ('MESH:D013922', 'Disease') :: ['thrombocythemia']

entities_list: @entity1423 :: ('MESH:D001791', 'Disease') :: ['platelet defect']

entities_list: @entity3458 :: ('MESH:D000755', 'Disease') :: ['sickle cell disease']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic disease']

answer: @entity1423 :: (MESH:D001791,Disease) :: ['platelet disorders']